[시장보고서]차세대 유방암 진단 및 스크리닝 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 기술별, 바이오마커별, 암 서브타입별, 제공 서비스별, 최종사용자별, 지역별, 경쟁별 부문(2020-2030F)

차세대 유방암 진단 및 스크리닝 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 기술별, 바이오마커별, 암 서브타입별, 제공 서비스별, 최종사용자별, 지역별, 경쟁별 부문(2020-2030F)

Next-Generation Breast Cancer Diagnostic and Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Biomarker, By Cancer Sub-Type, By Offering, By End User, By Region and Competition, 2020-2030F

상품코드 : 1703259

리서치사 : TechSci Research

발행일 : 2025년 04월

페이지 정보 : 영문 187 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,462,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 7,899,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,489,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 차세대 유방암 진단 및 스크리닝 시장은 2024년에 46억 5,000만 달러로 평가되고, 예측 기간에는 85억 3,000만 달러에 달하며, 2030년까지 CAGR은 10.61%에 달할 것으로 예측됩니다.

차세대 유방암 진단 및 스크리닝법은 유방암을 발견하고 진단하기 위한 진보적이고 혁신적인 접근법을 의미합니다. 이 방법들은 유방암의 검출, 진단, 위험 평가의 정확성과 유효성을 향상시키기 위해 최첨단 기술, 분자적 인사이트, 개별화 접근법을 통합하고 있습니다. 차세대 방법은 특정 유전자 마커를 기반으로 유방암의 분자적 아형 분류를 가능하게 합니다. 이러한 아형 분류는 종양의 행동에 대한 인사이트를 제공하여 가장 적합한 치료 전략을 결정하는 데 도움을 줍니다. 일반적인 아형으로는 호르몬 수용체 양성 유방암, HER2 양성 유방암, 삼중음성 유방암 등이 있습니다. 전 세계 유방암 발병률 증가는 중요한 원동력이 되고 있습니다. 유방암 발병률이 지속적으로 증가함에 따라 유방암을 조기에 발견할 수 있는 첨단 진단법 및 검진법에 대한 수요도 증가하고 있습니다.

시장 개요
예측 기간	2026-2030
시장 규모 : 2024년	46억 5,000만 달러
시장 규모 : 2030년	85억 3,000만 달러
CAGR : 2025-2030년	10.61%
급성장 부문	차세대 시퀸서(NGS)
최대 시장	북미

유방 영상 진단, 유전자 검사, 분자진단의 지속적인 기술 발전으로 유방암의 정확도와 조기 발견이 향상되면서 이러한 기술에 대한 수요가 증가하고 있습니다. 맞춤형 의료로의 전환으로 환자의 유방암 아형과 유전자 프로파일에 대한 개인화된 정보를 제공하는 진단 검사에 대한 수요가 증가하고 있습니다. 이 정보는 치료 결정에 도움이 될 수 있습니다. 유방암 인식 개선 캠페인과 조기 발견을 장려하는 노력으로 더 많은 여성들이 정기적으로 유방암 검진을 받으면서 시장 성장에 기여하고 있습니다.

주요 시장 성장 촉진요인

기술의 진보

주요 시장이 해결해야 할 과제

윤리적·법적 문제

주요 시장 동향

멀티 오믹스 데이터의 통합

시장 규모·예측
- 금액별
시장 점유율·예측
- 기술별(실시간 PCR, 면역조직화학(IHC), 차세대 시퀀싱(NGS), 형광 in-situ 하이브리다이제이션(FISH), 기타)
- 바이오마커별(BRCA1/2, ER/PR수용체, HER-2, 기타)
- 암 서브타입별(루미날 A, 루미날 B, 삼중음성/기저세포 유사, 인간 상피 성장인자 수용체 2(HER-2) 농축)
- 제공 내용(제품, 서비스)
- 최종사용자별(병원, 진료소, 진단 센터, 표준실험실, 학술 조사기관)
- 지역별
- 기업별(2024)
시장 맵

제6장 아시아태평양의 차세대 유방암 진단 및 스크리닝 시장 전망

시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 호주
- 일본
- 한국

제7장 유럽의 차세대 유방암 진단 및 스크리닝 시장 전망

시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
- 프랑스
- 독일
- 스페인
- 이탈리아
- 영국

제8장 북미의 차세대 유방암 진단 및 스크리닝 시장 전망

시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
- 미국
- 멕시코
- 캐나다

제9장 남미의 차세대 유방암 진단 및 스크리닝 시장 전망

시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
- 브라질
- 아르헨티나
- 콜롬비아

제10장 중동 및 아프리카의 차세대 유방암 진단 및 스크리닝 시장 전망

시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트

제11장 시장 역학

촉진요인
과제

제12장 시장 동향과 발전

최근 동향
제품 출시
합병과 인수

제13장 세계의 차세대 유방암 진단 및 스크리닝 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협

제15장 PESTEL 분석

제16장 경쟁 구도

Abbott Laboratories
Agendia Inc.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
BGI Genomics Co., Ltd.
CENTOGENE N.V.
Danaher Corporation
Exact Sciences Corporation
F. Hoffmann-La Roche Ltd.
Illumina, Inc.
Thermo Fisher Scientific Inc.
Lucence Diagnostics Pte Ltd.

제17장 전략적 제안

제18장 조사회사 소개·면책사항

KSA

영문 목차

영문목차

Global Next-Generation Breast Cancer Diagnostic and Screening Market was valued at USD 4.65 Billion in 2024 and is expected to reach USD 8.53 Billion in the forecast period with a CAGR of 10.61% through 2030. Next-generation breast cancer diagnostic and screening methods refer to advanced and innovative approaches to detecting and diagnosing breast cancer. These methods incorporate cutting-edge technologies, molecular insights, and personalized approaches to improve the accuracy and effectiveness of breast cancer detection, diagnosis, and risk assessment. Next-generation methods enable the molecular subtyping of breast cancer based on specific genetic markers. This subtyping provides insights into the tumor's behavior and helps determine the most appropriate treatment strategy. Common subtypes include hormone receptor-positive, HER2-positive, and triple-negative breast cancer. The increasing incidence of breast cancer worldwide has been a significant driver. As breast cancer rates continue to rise, the demand for advanced diagnostic and screening methods to detect the disease at an early stage has also increased.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 4.65 Billion
Market Size 2030	USD 8.53 Billion
CAGR 2025-2030	10.61%
Fastest Growing Segment	Next-Generation Sequencing (NGS)
Largest Market	North America

Ongoing technological advancements in breast imaging, genetic testing, and molecular diagnostics have improved the accuracy and early detection of breast cancer, driving demand for these technologies. The shift toward personalized medicine has led to an increased demand for diagnostic tests that provide individualized information about a patient's breast cancer subtype and genetic profile. This information guides treatment decisions. Breast cancer awareness campaigns and initiatives promoting early detection have encouraged more women to undergo regular breast cancer screening, contributing to market growth.

Key Market Drivers

Advancements in Technology

Digital mammography has largely supplanted traditional film mammography, offering enhanced image quality, streamlined storage and retrieval, and the capability to manipulate images for improved visualization of breast tissue. As of June 2023, the U.S. Food and Drug Administration reported that 87% of mammography facilities in the United States have adopted 3D mammography systems, also known as breast tomosynthesis, which capture multiple X-ray images from different angles to create a three-dimensional representation of the breast. This technology has been shown to reduce false positives and improve cancer detection, particularly in women with dense breast tissue.

Breast Magnetic Resonance Imaging (MRI) utilizes powerful magnets and radio waves to generate detailed images of breast tissue, proving especially useful for assessing disease extent and detecting tumors in high-risk women. Advanced ultrasound technologies, including elastography and contrast-enhanced ultrasound, offer additional insights into breast lesions, aiding in distinguishing between benign and malignant tumors. Genetic testing has advanced with next-generation sequencing, allowing simultaneous analysis of multiple genes to comprehensively assess mutations associated with breast cancer.

Key Market Challenges

Ethical and Legal Issues

As next-generation diagnostic and screening methods generate large volumes of sensitive patient data, ensuring privacy and data security becomes paramount. Ethical concerns arise regarding the storage, sharing, and protection of patient genetic and medical information. Patients must provide informed consent before undergoing genetic testing or other screening procedures. Ensuring that patients fully understand the implications of the tests, including potential psychological and medical consequences, is an ethical imperative. Concerns about genetic discrimination in employment, insurance, and other areas may deter individuals from undergoing genetic testing. Legal protections against such discrimination are essential to address these concerns. Ethical and legal questions arise about who owns the genetic and medical data generated through screening. This includes issues related to data access, sharing, and commercialization. Next-generation screening technologies must adhere to regulatory standards to ensure safety, accuracy, and efficacy. Navigating the complex regulatory landscape can be a challenge for companies and healthcare providers. Ethical issues related to healthcare equity and access arise when next-generation screening technologies are not equally available to all populations. Disparities in access can lead to unequal health outcomes.

Key Market Trends

Integration of Multi-Omics Data

Multi-omics approaches enable healthcare providers to obtain a detailed profile of breast cancer at the molecular level. This includes information on genetic mutations, gene expression patterns, protein activity, metabolite levels, and epigenetic modifications. Integration of multi-omics data allows for precise molecular subtyping of breast cancer, which helps tailor treatment strategies based on the unique characteristics of each patient's tumor. This approach enhances the effectiveness of targeted therapies and minimizes unnecessary treatments. Multi-omics data analysis can identify biomarkers associated with early-stage breast cancer and risk prediction. This aids in early detection and risk assessment, enabling healthcare providers to intervene at an earlier, more treatable stage. Multi-omics analysis identifies specific molecular targets within breast cancer cells that can be exploited for treatment. This leads to the development of targeted therapies and more effective treatment options. Multi-omics data can be used to monitor a patient's response to treatment over time. Changes in gene expression, protein activity, or metabolite levels can indicate treatment efficacy or the need for therapeutic adjustments.

Key Market Players

Abbott Laboratories
Agendia Inc.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Genomics Co., Ltd.
CENTOGENE N.V
Danaher Corporation
Exact Sciences Corporation
Hoffmann-La Roche Ltd.
Illumina, Inc.
Thermo Fisher Scientific Inc.
Lucence Diagnostics Pte Ltd.

Report Scope:

In this report, the Global Next-Generation Breast Cancer Diagnostic and Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next-Generation Breast Cancer Diagnostic and Screening Market, By Technology:

Real-Time PCR
Immunohistochemistry (IHC)
Next-Generation Sequencing (NGS)
Fluorescence In-Situ Hybridization (FISH)
Others

Next-Generation Breast Cancer Diagnostic and Screening Market, By Biomarker:

BRCA1/2
ER/PR Receptors
HER-2
Others

Next-Generation Breast Cancer Diagnostic and Screening Market, By Cancer Sub-Type:

Luminal A
Luminal B
Triple Negative/Basal Like
Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched

Next-Generation Breast Cancer Diagnostic and Screening Market, By Offering:

Products
Services

Next-Generation Breast Cancer Diagnostic and Screening Market, By End User:

Hospitals and Clinics
Diagnostic Centers, and Reference Labs
Academic and Research Institutes

Next-Generation Breast Cancer Diagnostic and Screening Market, By region:

North America
- United States
- Canada
- Mexico
Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation Breast Cancer Diagnostic and Screening Market.

Available Customizations:

Global Next-Generation Breast Cancer Diagnostic and Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others)
- 5.2.2. By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others)
- 5.2.3. By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched)
- 5.2.4. By Offering (Products, Services)
- 5.2.5. By End User (Hospitals and Clinics, Diagnostic Centers, and Reference Labs, Academic and Research Institutes)
- 5.2.6. By Region
- 5.2.7. By Company (2024)
5.3. Market Map

6. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Technology
- 6.2.2. By Biomarker
- 6.2.3. By Cancer Sub-Type
- 6.2.4. By Offering
- 6.2.5. By End User
- 6.2.6. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Technology
    - 6.3.1.2.2. By Biomarker
    - 6.3.1.2.3. By Cancer Sub-Type
    - 6.3.1.2.4. By Offering
    - 6.3.1.2.5. By End User
- 6.3.2. India Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Technology
    - 6.3.2.2.2. By Biomarker
    - 6.3.2.2.3. By Cancer Sub-Type
    - 6.3.2.2.4. By Offering
    - 6.3.2.2.5. By End User
- 6.3.3. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Technology
    - 6.3.3.2.2. By Biomarker
    - 6.3.3.2.3. By Cancer Sub-Type
    - 6.3.3.2.4. By Offering
    - 6.3.3.2.5. By End User
- 6.3.4. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Technology
    - 6.3.4.2.2. By Biomarker
    - 6.3.4.2.3. By Cancer Sub-Type
    - 6.3.4.2.4. By Offering
    - 6.3.4.2.5. By End User
- 6.3.5. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Technology
    - 6.3.5.2.2. By Biomarker
    - 6.3.5.2.3. By Cancer Sub-Type
    - 6.3.5.2.4. By Offering
    - 6.3.5.2.5. By End User

7. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Technology
- 7.2.2. By Biomarker
- 7.2.3. By Cancer Sub-Type
- 7.2.4. By Offering
- 7.2.5. By End User
- 7.2.6. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Technology
    - 7.3.1.2.2. By Biomarker
    - 7.3.1.2.3. By Cancer Sub-Type
    - 7.3.1.2.4. By Offering
    - 7.3.1.2.5. By End User
- 7.3.2. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Technology
    - 7.3.2.2.2. By Biomarker
    - 7.3.2.2.3. By Cancer Sub-Type
    - 7.3.2.2.4. By Offering
    - 7.3.2.2.5. By End User
- 7.3.3. Spain Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Technology
    - 7.3.3.2.2. By Biomarker
    - 7.3.3.2.3. By Cancer Sub-Type
    - 7.3.3.2.4. By Offering
    - 7.3.3.2.5. By End User
- 7.3.4. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Technology
    - 7.3.4.2.2. By Biomarker
    - 7.3.4.2.3. By Cancer Sub-Type
    - 7.3.4.2.4. By Offering
    - 7.3.4.2.5. By End User
- 7.3.5. United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Technology
    - 7.3.5.2.2. By Biomarker
    - 7.3.5.2.3. By Cancer Sub-Type
    - 7.3.5.2.4. By Offering
    - 7.3.5.2.5. By End User

8. North America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Technology
- 8.2.2. By Biomarker
- 8.2.3. By Cancer Sub-Type
- 8.2.4. By Offering
- 8.2.5. By End User
- 8.2.6. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Technology
    - 8.3.1.2.2. By Biomarker
    - 8.3.1.2.3. By Cancer Sub-Type
    - 8.3.1.2.4. By Offering
    - 8.3.1.2.5. By End User
- 8.3.2. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Technology
    - 8.3.2.2.2. By Biomarker
    - 8.3.2.2.3. By Cancer Sub-Type
    - 8.3.2.2.4. By Offering
    - 8.3.2.2.5. By End User
- 8.3.3. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Technology
    - 8.3.3.2.2. By Biomarker
    - 8.3.3.2.3. By Cancer Sub-Type
    - 8.3.3.2.4. By Offering
    - 8.3.3.2.5. By End User

9. South America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Technology
- 9.2.2. By Biomarker
- 9.2.3. By Cancer Sub-Type
- 9.2.4. By Offering
- 9.2.5. By End User
- 9.2.6. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Technology
    - 9.3.1.2.2. By Biomarker
    - 9.3.1.2.3. By Cancer Sub-Type
    - 9.3.1.2.4. By Offering
    - 9.3.1.2.5. By End User
- 9.3.2. Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Technology
    - 9.3.2.2.2. By Biomarker
    - 9.3.2.2.3. By Cancer Sub-Type
    - 9.3.2.2.4. By Offering
    - 9.3.2.2.5. By End User
- 9.3.3. Colombia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Technology
    - 9.3.3.2.2. By Biomarker
    - 9.3.3.2.3. By Cancer Sub-Type
    - 9.3.3.2.4. By Offering
    - 9.3.3.2.5. By End User

10. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Technology
- 10.2.2. By Biomarker
- 10.2.3. By Cancer Sub-Type
- 10.2.4. By Offering
- 10.2.5. By End User
- 10.2.6. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Technology
    - 10.3.1.2.2. By Biomarker
    - 10.3.1.2.3. By Cancer Sub-Type
    - 10.3.1.2.4. By Offering
    - 10.3.1.2.5. By End User
- 10.3.2. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Technology
    - 10.3.2.2.2. By Biomarker
    - 10.3.2.2.3. By Cancer Sub-Type
    - 10.3.2.2.4. By Offering
    - 10.3.2.2.5. By End User
- 10.3.3. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Technology
    - 10.3.3.2.2. By Biomarker
    - 10.3.3.2.3. By Cancer Sub-Type
    - 10.3.3.2.4. By Offering
    - 10.3.3.2.5. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Next-Generation Breast Cancer Diagnostic and Screening Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1. Abbott Laboratories
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
16.2. Agendia Inc.
16.3. Agilent Technologies, Inc.
16.4. Bio-Rad Laboratories, Inc.
16.5. BGI Genomics Co., Ltd.
16.6. CENTOGENE N.V.
16.7. Danaher Corporation
16.8. Exact Sciences Corporation
16.9. F. Hoffmann-La Roche Ltd.
16.10. Illumina, Inc.
16.11. Thermo Fisher Scientific Inc.
16.12. Lucence Diagnostics Pte Ltd.